Cargando…

Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review

Lung, breast, and esophageal cancer represent three common malignancies with high incidence and mortality worldwide. The management of these tumors critically relies on radiotherapy as a major part of multi-modality care, and treatment-related toxicities, such as radiation-induced pneumonitis and/or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Käsmann, Lukas, Dietrich, Alexander, Staab-Weijnitz, Claudia A., Manapov, Farkhad, Behr, Jürgen, Rimner, Andreas, Jeremic, Branislav, Senan, Suresh, De Ruysscher, Dirk, Lauber, Kirsten, Belka, Claus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488099/ https://www.ncbi.nlm.nih.gov/pubmed/32912295 http://dx.doi.org/10.1186/s13014-020-01654-9

Ejemplares similares

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Timing of tumor-induced atelectasis resolution and pulmonary function restoration in the course of image-guided moderate hypofractionated thoracic irradiation: a case report and mini-review of literature
por: Bodensohn, Raphael, et al.
Publicado: (2021)

Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic
por: Käsmann, Lukas, et al.
Publicado: (2022)

Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes
por: Manapov, Farkhad, et al.
Publicado: (2018)

Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis
por: Karin, Monika, et al.
Publicado: (2020)

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting
por: Taugner, Julian, et al.
Publicado: (2021)

Chemo-/immuno-/radiotherapy combination in treatment of solid cancer
por: Käsmann, Lukas, et al.
Publicado: (2019)

NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer
por: Manapov, Farkhad, et al.
Publicado: (2022)

Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis
por: Eze, Chukwuka, et al.
Publicado: (2019)

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
por: Käsmann, Lukas, et al.
Publicado: (2020)

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer
por: Taugner, Julian, et al.
Publicado: (2020)

In regards to Chu et al.: Patterns of brain metastasis immediately before prophylactic cranial irradiation (PCI): implications for PCI optimization in limited-stage small cell lung cancer
por: Käsmann, Lukas, et al.
Publicado: (2020)

Positron Emission Tomography/Computed Tomography (PET/CT)-Based, Local Consolidative Radiotherapy after Chemoimmunotherapy in Metastatic, Non-Oncogene-Addicted Non-Small-Cell Lung Cancer (NSCLC)
por: Angelini, Lucia, et al.
Publicado: (2023)

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
por: Käsmann, Lukas, et al.
Publicado: (2023)

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis
por: Flörsch, Benedikt, et al.
Publicado: (2022)

PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions
por: Eze, Chukwuka, et al.
Publicado: (2021)

Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy
por: Roengvoraphoj, Olarn, et al.
Publicado: (2020)

Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Gennen, Kathrin, et al.
Publicado: (2020)

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition
por: Taugner, Julian, et al.
Publicado: (2021)

Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients
por: Augustin, Teresa, et al.
Publicado: (2020)

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
por: Unterrainer, Marcus, et al.
Publicado: (2021)

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study
por: Käsmann, Lukas, et al.
Publicado: (2023)

MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: a report proposing a new clinical pathway for the management of high-risk patients
por: Eze, Chukwuka, et al.
Publicado: (2022)

Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy
por: Manapov, Farkhad, et al.
Publicado: (2013)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2021)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Automated biological target volume delineation for radiotherapy treatment planning using FDG-PET/CT
por: Niyazi, Maximilian, et al.
Publicado: (2013)

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
por: Guggenberger, J., et al.
Publicado: (2022)

FK506-binding protein 10 (FKBP10) regulates lung fibroblast migration via collagen VI synthesis
por: Knüppel, Larissa, et al.
Publicado: (2018)

On the analysis of clonogenic survival data: Statistical alternatives to the linear-quadratic model
por: Unkel, Steffen, et al.
Publicado: (2016)

Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report
por: Schiopu, Sanziana R. I., et al.
Publicado: (2021)

Mature results of a randomized trial comparing two fractionation schedules of high dose rate endoluminal brachytherapy for the treatment of endobronchial tumors
por: Niemoeller, Olivier M, et al.
Publicado: (2013)

Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1–3 cerebral metastases
por: Schüttrumpf, Lars Hendrik, et al.
Publicado: (2014)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Immunological aspects of radiotherapy
por: Scheithauer, Heike, et al.
Publicado: (2014)

X-change symposium: status and future of modern radiation oncology—from technology to biology
por: Corradini, Stefanie, et al.
Publicado: (2021)

Stereotactic radiotherapy of intrapulmonary lesions: comparison of different dose calculation algorithms for Oncentra MasterPlan®
por: Troeller, Almut, et al.
Publicado: (2015)

Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients
por: Shi, Run, et al.
Publicado: (2021)

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis
por: Bodensohn, Raphael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0llukrp7slpgbaqre6gaqhnc45